Evidence map›Paper›PMID 36973702›Full record

Trial reportBMC women's health2023

The effect of vitamin D on the severity of dysmenorrhea and menstrual blood loss: a randomized clinical trial.

Azam Amzajerdi, Maryam Keshavarz, Elham Ghorbali, Sally Pezaro, Fatemeh Sarvi

Open access · goldFull text readRandomized Controlled Trial
In one paragraph

Trial report in BMC women's health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Azam AmzajerdiSchool of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
Maryam KeshavarzDepartment of Midwifery and Reproductive Health, School of Nursing and Midwifery, Reproductive Sciences and Technology Research Center, Department of Midwifery and Reproductive Health, Iran University of Medical Sciences, Rashid Yasemi St., Valiasr St, Tehran, 1996713883, Iran. keshavarz.m@iums.ac.ir.ORCID 0000-0001-7776-8171
Elham GhorbaliSchool of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
Sally PezaroCentre for Healthcare Research, Coventry University, Coventry, UK.
Fatemeh SarviDepartment of Public Health, School of Health, Larestan University of Medical Sciences, Shiraz, Fars, Iran.
Iranshahr University · IRCoventry University · GBIran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary dysmenorrhea is considered as one of the women's main problems during reproductive age. The present study aimed to investigate the effect of vitamin D on the severity of dysmenorrhea and menstrual blood loss.

methodsThis double-blind, randomized, placebo-controlled trial, was performed on 84 single female college students between 18 and 25 years old who living in dormitories. Students with primary dysmenorrhea and vitamin D deficiency were divided into experimental (n = 42) and control (n = 42) groups. Five days before the putative beginning of their next menstrual cycle, the experimental group received 300,000 IU vitamin D (50,000 IU, two tablets every 8 h), and the control group received a placebo (oral paraffin). The effects of the supplement on the severity of dysmenorrhea and menstrual blood loss were evaluated one cycle before and during two successive cycles. Using the visual analog scale (VAS), verbal multidimensional scoring system (VMS), and pictorial blood assessment chart (PBLAC) questionnaires. Fisher's exact, Chi-square, independent sample t-test and repeated measurements were used.

resultsIn total, 78 of the 84 students completed the study (39 students per group). The intervention resulted in a significant reduction in the mean scores of both the VAS and VMS in the experimental group, in the first and second menstrual cycles (p < 0.001, p < 0.001, respectively), but not in the means score of PBLAC. Mefenamic acid consumption at the first and second menstruation period, in the experimental group was lower than the control group (p = 0.009, p < 0.001, respectively).

conclusionsThe results indicate that vitamin D supplementation could decrease the severity of primary dysmenorrhea and the need to consume pain-relief medications. Contrariwise vitamin D supplementation had no significant effect on menstrual blood loss.

trial registrationThis trial was registered in the Iranian Registry of Clinical Trials with code IRCT201305212324N on 18/1/2014. URL of registry: https://en.irct.ir/trial/1964 .

Indexed as

DysmenorrheaMenstruationAdolescentAdultFemaleHemorrhageHumansIranMefenamic AcidVitamin DYoung AdultMefenamic AcidVitamin DMenstrual blood lossPrimary dysmenorrheaUniversity studentsVitamin D

Identifiers

PMID36973702
PMCPMC10045437
OpenAlexW4360997884

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read46
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.